|
Dear Colleagues,
Thank you for your continued interest in the online webinars organized by the IAEA Radiation Protection of Patients Unit (RPOP).
We are pleased to invite you to our next webinar on Release of Patients After Radionuclide Therapy: Radiation Protection Considerations. It will be held on Tuesday, 23 September 2025, at 3:00 PM CEST (Vienna time), in English.
As the use of radiopharmaceuticals in therapy continues to expand, it is increasingly important to address the radiation protection challenges associated with patient release and post-treatment scenarios, including the death of a patient following therapy.
This webinar will explore regulatory, public and occupational safety aspects related to the release of patients after radionuclide therapy and the safe handling of deceased patients who have recently undergone such treatments. It will address measures to protect family members, the general public, healthcare workers and funeral professionals from potential radiation exposure in these scenarios.
Tailored for a broad audience — including nuclear medicine physicians, technologists, nurses, radiation protection officers, medical physicists, regulators, funeral professionals and hospital administrators — this session will feature expert-led presentations followed by a live discussion.
Participants will gain practical insights into current guidelines, real world practices and emerging challenges in this important area of radiation protection.
Through this webinar, you will learn how to:
- Recognize the regulatory criteria for releasing patients following radionuclide therapy;
- Identify main risks and protective measures for family members, the public, and the healthcare environment following radionuclide therapy;
- Review dose assessment methods and regulatory criteria used to determine the safe release of patients following radionuclide therapy;
- Examine exposure scenarios, dose assessment methods and safety recommendations for undertakers (including transport and embalming) and crematorium staff following the death of patients after radionuclide therapy.
More information can be found here.
We look forward to seeing you.
RPOP Team
|
